1 – 18 of 18
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer : A subgroup analysis of the randomised clinical TITAN study
(
- Contribution to journal › Article
- 2021
-
Mark
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer : Analysis of Pain and Fatigue in the Phase 3 TITAN Study
(
- Contribution to journal › Article
-
Mark
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer : Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
2021) In Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39(20). p.2294-2303(
- Contribution to journal › Article
- 2020
-
Mark
Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses : A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel
(
- Contribution to journal › Article
- 2019
-
Mark
European Association of Urology Guidelines on Renal Cell Carcinoma : The 2019 Update
(
- Contribution to journal › Article
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN) : a randomised, placebo-controlled, phase 3 study
(
- Contribution to journal › Article
-
Mark
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Updated European Association of Urology Guidelines : Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
(
- Contribution to journal › Article
-
Mark
Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition : The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations
(
- Contribution to journal › Letter
- 2017
-
Mark
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy.
(
- Contribution to journal › Scientific review
- 2015
-
Mark
Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations
(
- Contribution to journal › Article
-
Mark
EAU Guidelines on Renal Cell Carcinoma: 2014 Update.
(
- Contribution to journal › Article
-
Mark
Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus.
2015) In European Urology(
- Contribution to journal › Scientific review